Observational studyInternal medicine journal2026
Methicillin-resistant Staphylococcus aureus bloodstream infections in the Northern Territory of Australia 2017-2022.
Observational study in Internal medicine journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Complexity and comorbidities: critical considerations for methicillin-resistant Staphylococcus aureus bacteraemia outcomes in the Northern Territory.Internal medicine journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMethicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSIs) cause significant morbidity and mortality. In Australia's Northern Territory (NT), MRSA BSI prevalence is disproportionately high. Vancomycin remains standard therapy despite toxicity and complex monitoring requirements.
aimTo evaluate demographics, clinical management and outcomes of patients with MRSA BSI in the NT, with a focus on health inequities.
methodsThis multi-centre retrospective observational study analysed MRSA BSI episodes in hospitalised adults between 2017 and 2022 at the Royal Darwin and Alice Springs Hospitals. Key data were extracted from electronic medical records. Composite treatment failure was defined as follows: outcome of all-cause 90-day mortality, persistent bacteraemia (>7 days) or 90 day relapse.
resultsOf 182 identified episodes, MRSA accounted for 40% of all S. aureus BSIs. First Nations Australians were disproportionately affected, representing 69% of episodes, with an incidence rate 3.3 times higher than non-Indigenous residents. The composite treatment failure rate was 18%, and 90-day mortality was 13%. Age ≥ 50 years was the only independent variable associated with treatment failure. Notably, 19% of patients required an antimicrobial switch from vancomycin, frequently due to adverse drug reactions. Vancomycin minimum inhibitory concentration (MIC) testing showed high discordance between VITEK2 and E-Test.
conclusionMRSA bloodstream infections remain a significant challenge in the NT, largely due to social and structural factors disproportionately affecting First Nations Australians. While strategies to prevent invasive bloodstream infections should be prioritised, the high incidence of vancomycin-related adverse events and MIC discordance underscores the urgent need for stable, effective oral antimicrobial alternatives and culturally safe, community-led prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.